Protein Kinase C Isozymes as Potential Targets for Anticancer Therapy

Current Cancer Drug Targets

Volumn 4, Issue 2, 2004, Pages 125-146

  Hofmann, Johann ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 7 HYDROXYSTAUROSPORINE; ANTISENSE OLIGONUCLEOTIDE; BRYOSTATIN 1; CISPLATIN; DAUNORUBICIN; DOXORUBICIN; EDELFOSINE; ILMOFOSINE; MIDOSTAURIN; MILTEFOSINE; N BENZYLDOXORUBICIN 14 VALERATE; PHOSPHOLIPID DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C BETA1; PROTEIN KINASE C BETA2; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C GAMMA; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE C THETA; PROTEIN KINASE C ZETA; ROTTLERIN; RUBOXISTAURIN; STAUROSPORINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALRUBICIN; VINBLASTINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; BREAST METASTASIS; CANCER INHIBITION; CANCER PATIENT; CANCER THERAPY; CARCINOGENESIS; CARDIOTOXICITY; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; DIABETIC RETINOPATHY; DRUG POTENTIATION; ENZYME ACTIVATION; FATIGUE; FEVER; HEADACHE; HUMAN; ION CURRENT; METASTASIS; MYALGIA; NONHODGKIN LYMPHOMA; PHLEBITIS; REVIEW; SIGNAL TRANSDUCTION; SKIN METASTASIS; SOLID TUMOR; SYNAPTIC TRANSMISSION; THROMBOCYTOPENIA;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; ISOENZYMES; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN KINASE C;

EID: 1542619344     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009043481579     Document Type: Review

References (286)

1. Nishizuka, Y. Protein Kinase C and Lipid Signaling for Sustained Cellular Responses. FASEB J. 1995, 9, 484-496.
2. Newton, A. C.; Johnson, J. E. Protein kinase C: A Paradigm for Regulation of Protein Function by Two Membrane-Targeting Modules. Biochim. Biophys. Act, 1998, 1376, 155-172.
3. Newton, A. C. Regulation of ABC Kinases by Phosphorylation: Protein Kinase C as a Paradigm. Biochem. J. 2003, 370, 361-371,
4. Stabel, S.; Parker, P. J. Protein Kinase C. Pharmacol. Ther. 1991, 41, 71-95.
5. Azzi, A.; Boscoboinik, D.; Hensey, C. The Protein Kinase C and Protein Kinase C Related Gene Families. Eur. J. Biochem. 1992, 208, 547-557.
6. Hug, H.; Sarre, T. F. Protein Kinase Isozymes: Divergence in Signal Transduction? Biochem. J. 1993, 291, 329-343.
7. Blobe, G. C.; Stribling, S.; Obeid, L. M.; Hannun, Y. A. Protein Kinase C Isoenzymes: Regulation and Function. Cancer Surv. 1996, 27, 213-248.
8. Liu, W. S.; Heckman, C. A. The Sevenfold Way of PKC Regulation. Cell. Signal. 1998, 10, 529-542.
9. Dutil, E. M.; Toker, A.; Newton, A. C. Regulation of Conventional Protein Kinase C Isozymes by Phosphoinositide-Dependent Kinase 1 (PDK-1). Curr. Biol. 1998, 8, 1366-1375.
10. Le Good, A. J.; Ziegler, W. H.; Parekh, D. B.; Alessi, D. R.; Cohen, P.; Parker P. J. Protein Kinase C Isotypes Controlled by Phosphoinositide-3-Kinase Through the Protein Kinase PDK1. Science 1998, 281, 2042-2045.
11. Parekh, D. B.; Ziegler, W.; Parker, P. J. Multiple Pathways Control Protein Kinase C Phosphorylation. EMBO J. 2000, 19, 496-503.
12. Hansra, G.; Bornancin, F.; Whelan, R.; Hemmings, B. A.; Parker, P. J. 12-O-Tetradecanoylphorbol-13-Acetate-Induced Dephosphorylation of Protein Kinase C Alpha Correlates with the Presence of a Membrane-Associated Protein Phosphatase 2A Heterotrimer. J. Biol. Chem. 1996, 271, 32785-32788.
13. Lozano, J.; Berra, E.; Municio, M. M.; Diaz-Meco, M. T.; Dominguez, I.; Sanz, L.; Moscat, J. Protein Kinase C Zeta Isoform is Critical for Kappa B-Dependent Promoter Activation by Sphingomyelinase. J. Biol. Chem. 1994, 269, 19200-19202.
14. Nakanishi, H.; Brewer, K. A.; Exton, J. H. Activation of the Zeta Isozyme of Protein Kinase C by Phosphatidylinositol 3,4,5-Trisphosphate. J. Biol. Chem. 1993, 268, 13-16.
15. 2+, Phosphatidylinositol and Phosphatidylinositol 4,5-Bisphosphate. Biochem. J. 1993, 291, 627-633.
16. Ikuta, T.; Chida, K.; Tajima, O.; Matsuura, Y.; Iwamori, M.; Ueda, Y.; Mizuno, K.; Ohno, S.; Kuroki, T. Cholesterol Sulfate, a Novel Activator of the η Isoform of Protein Kinase C. Cell Growth Differ. 1994, 5, 943-947.
17. (2+) Bridges the C2 Membrane-Binding Domain of Protein Kinase C Alpha Directly to Phosphatidylserine. EMBO J. 1999, 18, 6329-6338.
18. Oancea, E.; Meyer, T. Protein Kinase C as a Molecular Machine for Decoding Calcium and Diacylglycerol Signals. Cell 1998, 95, 307-318.
19. Goekjian, P. G.; Jirousek, M. R. Protein Kinase C Inhibitors as Novel Anticancer Drugs. Expert Opin. Investig. Drugs 2001, 10, 2117-2140.
20. Basu, A. The Potential of Protein Kinase C as a Target for Anticancer Treatment. Pharmacol. Ther. 1993, 59, 257-280.
21. Blobe, G. C.; Obeid, L. M.; Hannun, Y. A. Regulation of Protein Kinase C and Role in Cancer Biology. Cancer Metastasis Rev. 1994, 13, 411-431.
22. Gescher, A. Analogs of Staurosporine: Potential Anticancer Drugs? Gen. Pharmac. 1998, 31, 721-728.
23. Deacon, E. M.; Pongracz, J.; Griffiths, G.; Lord, J. M. Isozymes of Protein Kinase C: Differential Involvement in Apoptosis and Pathogenesis. J. Clin. Pathol: Mol. Pathol. 1997, 50, 124-131.
24. Schechtman, D.; Mochly-Rosen, D. Adaptor Proteins in Protein Kinase C-Mediated Signal Transduction. Oncogene 2001, 20, 6339-6347.
25. Moscat, J.; Diaz-Meco, M. T. The Atypical Protein Kinase Cs. Functional Specificity Mediated by Specific Protein Adapters. EMBO Reports 2000, 1, 399-403.
26. Ron, D.; Luo, J.; Mochly-Rosen, D. C2 Region-Derived Peptides Inhibit Translocation and Function for Beta Protein Kinase C in Vivo. J. Biol. Chem. 1995, 270, 24180-24187.
27. Mackay, K.; Mochly-Rosen, D. Localization, Anchoring and Functions of Protein Kinase C Isozymes in the Heart. J. Mol. Cell. Cardiol. 2001, 33, 1301-1307.
28. Mayne, G. C.; Murray, A. W. Evidence that Protein Kinase Cε Mediates Phorbol Ester Inhibition of Calphostin C- and Tumor Necrosis Factor-α-Induced Apoptosis in U937 Histiocytic Lymphoma Cells. J. Biol. Chem. 1998, 273, 24115-24121.
29. Acs, P.; Wang, Q. J.; Bogi, K.; Marquez, A. M.; Lorenzo, P. S.; Biro, T. ; Szallasi, Z.; Mushinski, J. F.; Blumberg, P. M. Both the Catalytic and Regulatory Domains of Protein Kinase C Chimeras Modulate the Proliferative Properties of NIH 3T3 Cells. J. Biol. Chem. 1997, 272, 28793-28799.
30. Mischak, H.; Goodnight, J. A.; Kölch, W.; Martiny-Baron, G.; Schaechtele, C.; Kazanietz, M. G.; Blumberg, P. M.; Pierce, J. H.; Mushinski, J. F. Overexpression of Protein Kinase C-Delta and -Epsilon in NIH 3T3 Cells Induces Opposite Effects on Growth, Morphology, Anchorage Dependence, and Tumorigenicity. J. Biol. Chem. 1993, 268, 6090-6096.
31. Cacace, A. M.; Guadagno, S. N.; Krauss, R. S.; Fabbro, D.; Weinstein, I. B. The Epsilon Isoform of Protein Kinase C is an Oncogene when Overexpressed in Rat Fibroblasts. Oncogene 1993, 8, 2095-2104.
32. Perletti, G. P.; Folini, M.; Lin, H. C.; Mischak, H.; Piccinini, F.; Tashjian, A. H. Jr. Overexpression of Protein Kinase C Epsilon is Oncogenic in Rat Colonic Epithelial Cells. Oncogene 1996, 12, 847-854.
33. Jansen, A. P.; Verwiebe, E. G.; Dreckschmidt, N. E.; Wheeler, D. L.; Oberley, T. D.; Verma, A. K. Protein Kinase C-Epsilon Transgenic Mice: a Unique Model for Metastatic Squamous Cell Carcinoma. Cancer Res. 2001, 61, 808-812.
34. Reddig, P. J.; Dreckschmidt, N. E.; Zou, J.; Bourguignon, S. E.; Oberley, T. D.; Verma, A. K. Transgenic Mice Overexpressing Protein Kinase C Epsilon in their Epidermis Exhibit Reduced Papilloma Burden but Enhanced Carcinoma Formation after Tumor Promotion. Cancer Res. 2000, 60, 595-602.
35. Baxter, G.; Oto, E.; Daniel-Issakani, S.; Strulovici, B. Constitutive Presence of a Catalytic Fragment of Protein Kinase Cε in a Small Cell Lung Carcinoma Cell Line. J. Biol. Chem. 1992, 267, 1910-1917.
36. Wu, D.; Foreman, T. L.; Gregory, C. W; McJilton, M. A.; Wescott, G. G.; Ford, O. H.; Alvey, R. F.; Mohler, J. L.; Terrian, D. M. Protein Kinase C Epsilon has the Potential to Advance the Recurrence of Human Prostate Cancer. Cancer Res. 2002, 62, 2423-2429.
37. Lavie, Y.; Zhang, Z. C.; Cao, H-T.; Han, T-Y.; Johnes, R. C.; Liu, Y. Y. ; Jarman, M.; Hardcastle, I. R.; Giuliano, A. E.; Cabot, M. C. Tamoxifen Induces Selective Membrane Association of Protein Kinase C Epsilon in MCF-7 Human Breast Cancer Cells. Int. J. Cancer 1998, 77, 928-932.
38. Dorn II, G. W.; Mochly-Rosen, D. Intracellular Transport Mechanisms of Signal Transducers. Annu. Rev. Physiol. 2002, 64, 407-729.
39. Gschwendt, M. Protein Kinase Cδ. Eur. J. Biochem. 1999, 259, 555-564.
40. Kikkawa, U.; Matsuzaki, H.; Yamamoto, T. Protein Kinase Cδ (PKCδ): Activation Mechanisms and Functions. J. Biochem. 2002, 132, 831-839.
41. Das, K. C.; Guo, X.; White, C. W. Protein Kinase Cδ-Dependent Induction of Manganese Superoxide Dismutase Gene Expression by Microtubule-Active Anticancer Drugs. J. Biol. Chem. 1998, 273, 34639-34645.
42. Lothstein, L.; Israel, M.; Sweatman, T. W. Anthracycline Drug Targeting: Cytoplasmic Versus Nuclear. Drug Res. Updates 2001, 4, 169-177.
43. Clark. A. S.; West, K. A.; Blumberg, P. M.; Dennis, P. A. Altered Protein Kinase C (PKC) Isoforms in Non-Small Cell Lung Cancer Cells: PKCdelta Promotes Cellular Survival and Chemotherapeutic Resistance. Cancer Res. 2003, 63, 780-786.
44. Fagerstrom, S.; Pahlman, S.; Gestblom, C.; Nanberg, E. Protein Kinase C-Epsilon is Implicated in Neurite Outgrowth in Differentiating Human Neuroblastoma Cells. Cell Growth Differ. 1996, 7, 775-785.
45. Mishima, K.; Ohno, S.; Shitara, N.; Yamaoka, K.; Suzuki, K. Opposite Effects of the Overexpression of Protein Kinase C Gamma and Delta on the Growth Properties of Human Glioma Cell Line U251 MG. Biochem. Biophys. Res. Commun. 1994, 201, 363-372.
46. Mandil, R.; Ashkenazi, E.; Blass, M.; Kronfeld, I.; Kazimirsky, G.; Rosenthal, G.; Umansky, F.; Lorenzo, P. S.; Blumberg, P. M.; Brodie, C. Protein Kinase C Alpha and Protein Kinase C Delta Play Opposite Roles in the Proliferation and Apoptosis of Glioma Cells. Cancer Res. 2001, 61, 4612-4619.
47. Zellner, A.; Fetell, M. R.; Bruce, J. N.; De Vivo, D. C.; O'Driscoll, K. R. Disparity in Expression of Protein Kinase C Alpha in Human Glioma Versus Glioma-Derived Primary Cell Lines: Therapeutic Implications. Clin. Cancer Res. 1998, 4, 1797-1802.
48. Benzil, D. L.; Finkelstein, S. D.; Epstein, M. H.; Finch, P. W. Expression Pattern of Alpha-Protein Kinase C in Human Astrocytomas Indicates a Role in Malignant Progression. Cancer Res. 1992, 52, 2951-2956.
49. Misra-Press, A.; Fields, A.P.; Samols, D.; Goldthwait, D. A. Protein Kinase C Isoforms in Human Glioblastoma Cells. Glia 1992, 6, 188-197.
50. Xiao, H.; Goldthwait, D. A.; Mapstone, T. The Identification of Four Protein Kinase C Isoforms in Human Glioblastoma Cell Lines: PKC Alpha, Gamma, Epsilon, and Zeta. J. Neurosurg. 1994, 81, 734-740.
51. Sharif, T. R.; Sharif, M. Overexpression of Protein Kinase C Epsilon in Astroglial Brain Tumor Derived Cell Lines and Primary Tumor Samples. Int. J. Oncol. 1999, 15, 237-243.
52. Hussaini, I. M.; Karns, L. R.; Vinton, G.; Carpenter, J. E.; Redpath, G. T.; Sando, J. J.; VandenBerg, S. R. Phorbol 12-Myristate 13-Acetate Induces Protein Kinase C Eta-Specific Proliferative Response in Astrocytic Tumor Cells. J. Biol. Chem. 2000, 275, 22348-22354.
53. Couldwell, W. T.; Antel, J. P.; Apuzzo, M. L.; Yong, V. W. Inhibition of Growth of Established Human Glioma Cell Lines by Modulators of the Protein Kinase-C System. J. Neurosurg. 1990, 73, 594-600.
54. Leirdal, M.; Sioud, M. Ribozyme Inhibition of the Protein Kinase C Alpha Triggers Apoptosis in Glioma Cells. Br. J. Cancer 1999, 80, 1558-1564.
55. Ways, K. D.; Kukoly, C. A.; deVente, J.; Hooker, J. L.; Bryant, W. O.; Posekany, K. J.; Fletcher, D. J.; Cook, P. P.; Parker P. J. MCF-7 Breast Cancer Cells Transfected with Protein Kinase C-α Exhibit Altered Expression of Other Protein Kinase C Isoforms and Display a More Aggressive Phenotype. J. Clin. Invest. 1995, 95, 1906-1915.
56. Noti, J. D. Adherence to Osteopontin via Alphavbeta3 Suppresses Phorbol Ester-Mediated Apoptosis in MCF-7 Breast Cancer Cells that Overexpress Protein Kinase C-Alpha. Int. J. Oncol. 2000, 17, 1237-1243.
57. Manni, A.; Buckwalter, E.; Etindi, R.; Kunselman, S.; Rossini, A.; Mauger, D.; Dabbs, D.; Demers, L. Induction of a Less Aggressive Breast Cancer Phenotype by Protein Kinase C-α and -β Overexpression. Cell Growth Differ. 1996, 7, 1187-1198.
58. Tonetti, D. A.; Chisamore, M. J.; Grdina, W.; Schurz, H. and Jordan, V. C. Stable Transfection of Protein Kinase C Alpha cDNA In Hormone-Dependent Breast Cancer Cell Lines. Br. J. Cancer. 2000, 83, 782-791.
59. Carey, I.; Noti, J. D. Isolation of Protein Kinase C-Alpha-Regulated cDNAs Associated with Breast Tumor Aggressiveness by Differential mRNA Display. Int. J. Oncol. 1999, 14, 951-956.
60. Sun, X. G.; Rotenberg, S. A. Overexpression of Protein Kinase C Alpha in MCF-10A Human Breast Cells Engenders Dramatic Alterations in Morphology, Proliferation, and Motility. Cell Growth Differ. 1999, 10, 343-352.
61. Li, H.; Zhao, L.; Yang, Z.; Funder, J. W.; Liu, J. P. Telomerase is Controlled by Protein Kinase C Alpha in Human Breast Cancer Cells. J. Biol. Chem. 1998, 273, 33436-33442.
62. Ng, T.; Squire, A.; Hansra, G.; Bornancin, F.; Prevostel, C.; Hanby, A.; Harris, W.; Barnes, D.; Schmidt, S.; Mellor, H.; Bastiaens, P. I.; Parker, P. J. Imaging Protein Kinase C Alpha Activation in Cells. Science 1999 283, 2085-2089.
63. Schondorf, T.; Kurbacher, C. M.; Becker, M.; Warm, M.; Kolhagen, H.; Gohring, U. J. Heterogeneity of Protein Kinase C Activity and PKC-Zeta Expression in Clinical Breast Carcinomas. Clin. Exp. Med. 2001, 1, 1-8.
64. Alvaro, V.; Levy, L.; Roche, A.; Peillon, F.; Querat, B.; Joubert, D. Invasive Pituitary Tumors Express a Point-Mutated Alpha-Protein Kinase C. J. Clin. Endocrinol. Metabol. 1993, 77, 1125-1129.
65. Prevostel, C.; Martin, A.; Alvaro, V.; Jaffiol, C.; Joubert, D. Protein Kinase C Alpha and Tumorigenesis of the Endocrine Gland. Horm. Res. 1997, 47, 140-144.
66. Vallentin, A.; Lo, T. C.; Joubert, D. A Single Point Mutation in the V3 Region Affects Protein Kinase C Alpha Targeting and Accumulation at Cell-Cell Contacts. Mol. Cell. Biol. 2001, 21, 3351-3363.
67. Prevostel, C.; Alvaro V.; de Boisvilliers F.; Martin A.; Jaffiol C.; Joubert, D. The Natural Protein Kinase C Alpha Mutant is Present in Human Thyroid Neoplasms. Oncogene 1995, 11, 669-674.
68. Jin, L.; Maeda, T.; Chandler, W. F.; Lloyd, R. V. Protein Kinase C (PKC) Activity and PKC Messenger RNAs in Human Pituitary Adenomas. Am. J. Pathol. 1993, 142, 569-578.
69. Chen, X.; Knauf, J. A.; Gonsky, R.; Wang, M.; Lai, E. H.; Chissoe, S.; Fagin, J.; Korenberg, J. R. From Amplification to Gene in Thyroid Cancer: a High-Resolution Mapped Bacterial-Artificial-Chromosome Resource for Cancer Chromosome Abberations Guides Gene Discovery after Comparative Genome Hybridization. Am. J. Hum. Genet. 1998, 63, 625-637.
70. Knauf, J. A.; Elisei, R.; Mochly-Rosen, D.; Liron, T.; Chen, X. N.; Gonsky, R.; Korenberg, J. R.; Fagin, J. A. Involvement of Protein Kinase C Epsilon (PKCepsilon) in Thyroid Cell Death. A Truncated Chimeric PKC Epsilon Cloned from a Thyroid Cancer Cell Line Protects Thyroid Cells from Apoptosis. J. Biol. Chem. 1999, 274, 23414-23425.
71. Mochly-Rosen, D.; Fagin, J. A.; Knauf, J. A.; Nikiforov, Y.; Liron, T.; Schechtman, D. Spontaneous Occurrence of an Inhibitor of Protein Kinase C Localization in a Thyroid Cancer Cell Line: Role in Thyroid Tumorigenesis. Adv. Enzyme Regul. 2001, 41, 87-97.
72. Kiley, S. C. PKC Isozymes and Myeloid Cell Differentiation. In: Protein Kinase C. Parker, P. J.; Dekker, L. V. Ed.; Springer, Heidelberg, 1997, pp. 121-129.
73. MacFarlane D. E.; Manzel, L. Activation of Beta-Isozyme of Protein Kinase C (PKC beta) is Necessary and Sufficient for Phorbol Ester-Induced Differentiation of HL-60 Promyelocytes. Studies with PKC Beta-Defective PET Mutant. J. Biol. Chem. 1994, 269, 4327-4331.
74. Slosberg, E. D.; Yao, Y.; Xing, F.; Ikui, A.; Jirousek, M. R.; Weinstein, I. B. The Protein Kinase C Beta-Specific Inhibitor LY379196 Blocks TPA-Induced Monocytic Differentiation of HL60 Cells. Mol. Carcinog. 2000, 27, 166-176.
75. Gruber, J. R.; Ohno, S.; Niles, R. M. Increased Expression of Protein Kinase C Alpha Plays a Key Role in Retinoic Acid-Induced Melanoma Differentiation. J. Biol. Chem. 1992, 267, 13356-13360.
76. Murray, N. R.; Baumgardner, G. P.; Burns D. J.; Fields, A. P. Protein Kinase C Isotypes in Human Erythroleukemia (K562) Cell Proliferation and Differentiation. Evidence that Beta II Protein Kinase C is Required for Proliferation. J. Biol. Chem. 1993, 268, 15847-15853.
77. Murray, N. R.; Thompson, L. J.; Fields, A. P. The Role of Protein Kinase C in Cellular Proliferation and Cell Cycle Control. In: Protein Kinase C. Parker, P. J. and Dekker, L.V. Ed.; Springer, Heidelberg, 1997, pp. 97-120.
78. Ways, D. K.; Posekany, K.; deVente, J.; Garris, T.; Chen, J.; Hooker, J. ; Qin, W.; Cook, P.; Fletcher, D.; Parker, P. J. Overexpression of Protein Kinase C Zeta Stimulates Leukemic Cell Differentiation. Cell Growth Differ. 1994, 5, 1195-1203.
79. Dieter, P.; Schwende, H. Protein Kinase C-Alpha and -Beta Play Antagonistic Roles in the Differentiation Process of THP-1 Cells. Cell. Signal. 2000, 12, 297-302.
80. Balasubramanian, N.; Advani, S. H.; Zingde, S. M. Protein Kinase C Isoforms in Normal and Chronic Myeloid Leukemic Neutrophils. Distinct Signal for PKC Alpha by Immunodetection on PVDF Membrane, Decreased Expression of PKC Alpha and Increased Expression of PKC Delta in Leukemic Neutrophils. Leuk. Res. 1998, 22, 597-604.
81. Yuspa, S. H. The Pathogenesis of Squamous Cell Cancer: Lessions Learned from Studies of Skin Carcinogenesis. J. Dermatol. Sci. 1998, 17, 1-7.
82. Geiges, D.; Marks, F.; Gschwendt, M. Loss of Protein Kinase Cδ from Human HaCaT Keratinocytes upon Ras Transfection is Mediated by TGFα. Exp. Cell Res. 1995, 219, 299-303.
83. Oka, M.; Ogita, K.; Ando, H.; Horikawa, T.; Hayashibe, K.; Saito, N.; Kikkawa, U.; Ichihashi, M. Deletion of Specific Protein Kinase C Subspecies in Human Melanoma Cells. J. Cell Physiol. 1996, 167, 406-412.
84. Gilhooly, E. M.; Morse-Gaudio, M.; Bianchi, L.; Reinhart, L.; Rose, D. P.; Connolly, J. M.; Reed J. A.; Albino, A. P. Loss of Expression of Protein Kinase C Beta is a Common Phenomenon in Human Malignant Melanoma: a Result of Transformation or Differentiation? Melanoma Res. 2001, 11, 355-369.
85. Krasagakis, K.; Fimmel, S.; Genten, D.; Eberle, J.; Quas, P.; Ziegler, W.; Haller, H.; Orfanos, C. E. Lack of Protein Kinase C (PKC)-Beta and Low PKC-Alpha, -Delta, -Epsilon, and -Zeta Isozyme Levels in Proliferating Human Melanoma Cells. Int. J. Oncol. 2002, 20, 865-871.
86. Assert, R.; Kruis, W.; Hardt, M.; Fischbach, W.; Schatz, H.; Pfeiffer, A. Expression of Protein-Kinase C (PKC)-α and β2 mRNA in Normal Mucosa, Adenomas, Cell Lines and Growth Arrest by PKC in Differentiated Colon T84 Cells. Gastroenterology 1993, 89 (Suppl. 1), A2521.
87. Saxon, M. L.; Zhao, X.; Black, J. D. Activation of Protein Kinase C Isozymes is Associated with Post-Mitotic Events in Intestinal Epithelial Cells in Situ. J. Cell Biol. 1994, 126, 747-763.
88. Scaglione-Sewell, B.; Abraham, C.; Bissonnette, M.; Skarosi, S. F.; Hart, J.; Davidson, N. O.; Wali, R. K.; Davis, B. H.; Sitrin, M.; Brasitus, T. A. Decreased PKC-Alpha Expression Increases Cellular Proliferation, Decreases Differentiation, and Enhances the Transformed Phenotype of CaCo-2 cells. Cancer Res. 1998, 58, 1074-1081.
89. Batlle, E.; Verdu, J.; Dominguez, D.; del Mont Llosas, M.; Diaz, V.; Loukili, N.; Paciucci, R.; Alameda, F.; de Herreros, A. G. Protein Kinase C-Alpha Activity Inversely Modulates Invasion and Growth of Intestinal Cells. J. Biol. Chem. 1998, 273, 15091-15098.
90. Chakrabarty, S.; Rajagopal, S.; Moskal, T. L. Protein Kinase Cα Controls the Adhesion but not the Antiproliferative Response of Human Colon Carcinoma Cells to Transforming Growth Factor β1: Identification of Two Distinct Branches of Post-Protein Kinase Cα Adhesion Signal Pathway. Lab. Invest. 1998, 78, 413-421.
91. O'Brian, C. A.; Ward, N. E.; Gravitt, K. R.; Gupta, K. P. The Tumor Promoter Receptor Protein Kinase C: a Novel Target for Chemoprevention and Therapy of Human Colon Cancer. Prog. Clin. Biol. Res. 1995, 391, 117-120.
92. Goldstein, D. R.; Cacace, A. M.; Weinstein, I. B. Overexpression of Protein Kinase C β1 in the SW480 Colon Cancer Cell Line Causes Growth Suppression. Carcinogenesis 1995, 16, 1121-1126.
93. Choi, P. M.; Tchou-Wong, K. M.; Weinstein, I. B. Overexpression of Protein Kinase C in HT29 Colon Cancer Cells Causes Growth Inhibition and Tumor Suppression. Mol. Cell. Biol. 1990, 10, 4650-4657.
94. Kahl-Rainer, P.; Karner-Hanusch, J.; Weiss, W.; Marian, B. Five of Six Protein Kinase C Isozymes Present in Normal Mucosa Show Reduced Protein Levels During Tumor Development in the Human Colon. Carcinogenesis 1994, 15, 779-782.
95. Levy, M. F.; Pocsidio, J.; Guillem, J. G.; Forde, K.; LoGerfo, P.; Weinstein, I. B. Decreased Levels of Protein Kinase C Enzyme Activity and Protein Kinase C mRNA in Primary Colon Tumors. Dis. Colon Rectum 1993, 36, 913-921.
96. Assert, R.; Kötter, R.; Bisping, G.; Scheppach, W.; Stahlnecker, E. ; Müller, K. M.; Dusel, G.; Schatz, H.; Pfeiffer, A. Anti-Proliferative Activity of Protein Kinase C in Apical Compartments of Human Colonic Crypts: Evidence for a Less Activated Protein Kinase C in Small Adenomas. Int. J. Cancer 1999, 80, 47-53.
97. Pongracz, J.; Clark, P.; Neoptolemous, J. P.; Lord, J. M. Expression of Protein Kinase C Isozymes in Colorectal Cancer Tissue and their Differential Activation by Different Bile Acids. Int. J. Cancer 1995, 61, 35-39.
98. Suga, K.; Sugimoto, I.; Ito, H.; Hashimoto, E. Down-Regulation of Protein Kinase C-Alpha Detected in Human Colorectal Cancer. Biochem. Mol. Biol. Int. 1998, 44, 523-528.
99. Murray, N. R.; Davidson L. A.; Chapkin, R. S.; Gustafson, W. C.; Schattenberg, D. G.; Fields AP. Overexpression of Protein Kinase C β11 Induces Colonic Hyperproliferation and Increased Sensitivity to Colon Carcinogenesis. J. Cell Biol. 1999, 145, 699-711.
100. Sauma, S.; Yan, Z.; Ohno, S.; Friedmann, E. Protein Kinase C β1 and Protein Kinase β2 Activate p57 Mitogen-Activated Protein Kinase and Block Differentiation in Colon Carcinoma Cells. Cell Growth Differ. 1996, 7, 587-594.
101. Cornford, P.; Evans, J.; Dodson, A.; Parsons, K.; Woolfenden, A.; Neoptolemos, J.; Foster, C. S. Protein Kinase C Isozyme Patterns Characteristically Modulated in Early Prostate Cancer. Am. J. Pathol. 1999, 154, 137-144.
102. Powell, C. T.; Brittis, N. J.; Stec, D.; Hug, H.; Heston, W. D.; Fair, W. R. Persistent Membrane Translocation of Protein Kinase C Alpha During 12-0-Tetradecanoylphorbol-13-Acetate-Induced Apoptosis of LNCaP Human Prostate Cancer Cells. Cell Growth Differ. 1996, 7, 419-428.
103. Orlandi, L.; Binda, M.; Folini, M.; Bearzatto, A.; Villa, R.; Daidone, M. G.; Zaffaroni, N. Ribozyme-Mediated Inhibition of PKC Alpha Sensitizes Androgen-Independent Human Prostate Cancer Cells to Cisplatin-Induced Apoptosis. Prostate 2003, 54, 133-143.
104. Tolcher, A. W.; Reyno, L.; Venner, P. M.; Ernst, S. D.; Moore, M.; Geary, R. S.; Chi, K.; Hall, S.; Walsh, W.; Dorr, A.; Eisenhauer, E. A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-Refractory Prostate Cancer. Clin. Cancer Res. 2002, 8, 2530-2535.
105. Whelan, R. D.; Parker, P. J. Oncogene Loss of Protein Kinase C Function Induces an Apoptotic Response. Oncogene 1998, 16, 1939-1944.
106. Dive C.; Hickman, J. A. Drug-Target Interactions - Only the First Step in the Commitment to a Programmed Cell-Death. Br. J. Cancer 1991, 64, 192-196.
107. Fisher, D. E. Apoptosis in Cancer Therapy: Crossing the Threshold. Cell 1994, 78, 539-542.
108. Dooley, N. P.; Baltuch, G. H.; Groome, N.; Villemure, J. G.; Yong, V. W. Apoptosis is Induced in Glioma Cells by Antisense Oligonucleotides to Protein Kinase C Alpha and is Enhanced by Cycloheximide. Neuroreport 1998, 9, 1727-1733.
109. Shen, L.; Glazer, R. I. Induction of Apoptosis in Glioblastoma Cells by Inhibition of Protein Kinase C and its Association with the Rapid Accumulation of p53 and Induction of the Insulin-Like Growth Factor-I-Binding-Protein-3. Biochem. Pharmacol. 1998, 55, 1711-1719.
110. Cheng, A. L.; Chuang, S. E.; Fine, R. L.; Yeh, K. H.; Liao, C. M.; Lay, J. D.; Chen, D. S. Inhibition of the Membrane Translocation and Activation of Protein Kinase C, and Potentiation of Doxorubicin-Induced Apoptosis of Hepatocellular Carcinoma Cells by Tamoxifen. Biochem. Pharmacol. 1998, 55, 523-531.
111. Chen, C. Y.; Faller, D. V. Selective Inhibition of Protein Kinase C Isozymes by Fas Ligation. J. Biol. Chem. 1999, 274, 15320-15328.
112. Kelly, M. L.; Tang, Y.; Rosensweig, N.; Clejan, S.; Beckman, B. S. Granulocyte-Macrophage Colony-Stimulating Factor Rescues TF-1 Leukemia Cells from Ionizing Radiation-Induced Apoptosis through a Pathway Mediated by Protein Kinase Cα. Blood 1998, 92, 416-424.
113. Keenan, C.; Thompson, S.; Knox, K.; Pears, C. Protein Kinase C-Alpha is Essential for Ramos-BL B Cell Survival. Cell. Immunol. 1999, 196, 104-109.
114. Haimovitz-Friedman, A.; Kan, C. C.; Ehleiter, D.; Persaud, R. S.; McLoughlin, M.; Fuks, Z.; Kolesnick, R. N. Ionizing Radiation Acts on Cellular Membranes to Generate Ceramide and Initiate Apoptosis. J. Exp. Med. 1994, 180, 525-535.
115. Powell, C. T.; Brittis, N. J.; Stec, D.; Hug, H.; Heston, W. D.; Fair, W. R. Persistent Membrane Translocation of Protein Kinase C Alpha During 12-0-Tetradecanoylphorbol-13-Acetate Induced Apoptosis of LNCaP Human Prostate Cancer Cells. Cell Growth Differ. 1996, 7, 419-428.
116. Garcia-Bermejo, M. L.; Leskow, F. C.; Fujii, T.; Wang, Q.; Blumberg, P. M.; Ohba, M.; Kuroki, T.; Han, K. C.; Lee, J.; Marquez, V. E.; Kazanietz, M. G. Diacylglycerol (DAG)-Lactones, a New Class of Protein Kinase C (PKC) Agonists, Induce Apoptosis in LNCaP Prostate Cancer Cells by Selective Activation of PKC Alpha. J. Biol. Chem. 2002, 277, 645-655.
117. Knox, K. A.; Johnson, G. D.; Gordon, J. A Study of Protein Kinase C Isozyme Distribution in Relation to Bcl-2 Expression During Apoptosis of Epithelial Cells in Vivo. Exp. Cell Res. 1993, 207, 68-73.
118. Lee, J. Y.; Hannun, Y. A.; Obeid, L. M. Ceramide Inactivates Cellular Protein Kinase C Alpha. J. Biol. Chem. 1996, 271, 13169-13174.
119. Musashi, M.; Ota, S.; Shiroshita, N. The Role of Protein Kinase C Isoforms in Cell Proliferation and Apoptosis. Int. J. Hematol. 2000, 72, 12-19.
120. Shao, R. G.; Cao, C. X.; Pommier, Y. Activation of PKC Alpha Downstream from Caspases During Apoptosis Induced by 7-Hydroxystaurosporine or the Topoisomerase Inhibitors, Camptothecin and Etoposide, in Human Myeloid Leukemia HL60 Cells. J. Biol. Chem. 1997, 272, 31321-31325.
121. Ruvolo, P. P.; Deng, X.; Carr, B. K.; May, W. S. A Functional Role for Mitochondrial Protein Kinase C Alpha in Bcl2 Phosphorylation and Suppression of Apoptosis. J. Biol. Chem. 1998, 273, 25436-25442.
122. Barr, L. F.; Campbell, S. E.; Baylin, S. Protein Kinase C-β11 Inhibits Cycling and Decreases c-Myc-Induced Apoptosis in Small Cell Lung Cancer Cells. Cell Growth Differ. 1997, 8, 381-392.
123. Pongracz, J.; Tuffley, W.; Johnson, G. D.; Deacon, E. M.; Burnett, D.; Stockley, R. A.; Lord, J. M. Changes in Protein Kinase C Isozyme Expression Associated with Apoptosis in U937 Myelomonocytic Cells. Exp. Cell Res. 1995, 218, 430-438.
124. Pongracz, J.; Deacon, E. M.; Johnson, G. D.; Burnett, D.; Lord, J. M. DOPPA Induces Cell Death But not Differentiation of U937 Cells: Evidence for the Involvement of PKC-Beta 1 in the Regulation of Apoptosis. Leuk. Res. 1996, 20, 319-326.
125. Laouar, A.; Glesne, D.; Huberman, E. Involvement of Protein Kinase C-Beta and Ceramide in Tumor Necrosis Factor-Alpha-Induced but not Fas-Induced Apoptosis of Human Myeloid Leukemia Cells. J. Biol. Chem. 1999, 274, 23526-23534.
126. Whitman, S. P.; Civoli, F.; Daniel, L. W. Protein Kinase C Beta11 Activation by 1-Beta-D-Arabinofuranosylcytosine is Antagonistic to Stimulation of Apoptosis and Bcl-2alpha Down-Regulation. J. Biol. Chem. 1997, 272, 23481-2384.
127. Emoto, Y.; Manome, Y.; Meinhardt, G.; Kisaki, H.; Kharbanda, S.; Robertson, M.; Ghayur, T.; Wong, W. W.; Kamen, R.; Weichselbaum, R.; Kufe, D. Proteolytic Activation of Protein Kinase C Delta by an ICE Like Protease in Apoptotic Cells. EMBO J. 1995, 14, 6148-6156.
128. Ghayur, T.; Hugunin, M.; Talanian, R. V.; Ratnofsky, S.; Quinlan, C.; Emoto, Y.; Pandey, P.; Datta, R.; Huang, Y.; Kharbanda, S.; Allen, H.; Kamen, R.; Wong, W.; Kufe, D. Proteolytic Activation of Protein Kinase C Delta by an ICE/CED 3 Like Protease Induces Characteristics of Apoptosis. J. Exp. Med. 1996, 184, 2399-2404.
129. Denning, M. F.; Wang, Y.; Nickoloff, B. J.; Wrone-Smith, T. Protein Kinase C Delta is Activated by Caspase-Dependent Proteolysis During Ultraviolet Radiation-Induced Apoptosis of Human Keratinocytes. J. Biol. Chem. 1998, 273, 29995-30002.
130. Griffiths, G.; Garrone, B.; Deacon, E.; Owen, P.; Pongracz, J.; Mead, G. ; Bradwell, A.; Watters, D.; Lord, J. The Polyether Bistratene A Activates Protein Kinase C-Delta and Induces Growth Arrest in HL60 Cells. Biochem. Biophys. Res. Commun. 1996, 222, 802-808.
131. Lothstein, L.; Israel, M.; Sweatman, T. W. Anthracycline Drug Targeting: Cytoplasmic Versus Nuclear. Drug Res. Updates 2001, 4, 169-177.
132. Basu, A.; Lu, D.; Sun, B.; Moor, A. N.; Akkaraju, G. R.; Huang, J. Proteolytic Activation of Protein Kinase C-Epsilon by Caspase-Mediated Processing and Transduction of Antiapoptotic Signals. J. Biol. Chem. 2002, 277, 41850-41856.
133. Bertolotto, C.; Maulon, L.; Filippa, N.; Baier, G.; Auberger, P. Protein Kinase C Theta and Epsilon Promote T-Cell Survival by a Rsk-Dependent Phosphorylation and Inactivation of Bad. J. Biol. Chem. 2000, 275, 37246-37250.
134. Ding, L.; Wang, H.; Lang, W.; Xiao, L. Protein Kinase C-Epsilon Promotes Survival of Lung Cancer Cells by Suppressing Apoptosis Through Dysregulation of the Mitochondrial Caspase Pathway. J. Biol. Chem. 2002, 277, 35305-35313.
135. Shinohara, H.; Kayagaki, N.; Yagita, H.; Oyaizu, N.; Ohba, M.; Kuroki, T.; Ikawa, Y. A Protective Role of PKCepsilon against TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis in Glioma Cells. Biochem. Biophys. Res. Commun. 2001, 284, 1162-1167.
136. Koriyma, H.; Kouchi, Z.; Umeda, T.; Saido, T. C.; Momoi, T.; Ishiura, S. ; Suzuki, K. Proteolytic Activation of Protein Kinase C δ and ε by Caspase-3 in U937 Cells During Chemotherapeutic Agent-Induced Apoptosis. Cell. Signal. 1999, 11, 831-838.
137. Lee, H. Z. Protein Kinase C Involvement in Aloe-Emodin- and Emodin-Induced Apoptosis in Lung Carcinoma Cells. Br. J. Pharmacol. 2001, 134, 1093-1103.
138. Hussaini, I. M.; Carpenter, J. E.; Dedpath, G. T.; Sando, J. J.; Shaffrey, M. E.; VandenBerg, S. R. Protein Kinase C-Eta Regulates Resistance to UV- and gamma-Irradiation-Induced Apoptosis in Glioblastoma Cells by Preventing Caspase-9 Activation. Neuro-Oncol. 2002, 4, 9-21.
139. Datta, R.; Kojima, H.; Yoshida, K.; Kufe, D. Caspase 3 Mediated Cleavage of Protein Kinase C Theta in Induction of Apoptosis. J. Biol. Chem. 1997, 272, 20317-20320.
140. Murray, N. R.; Fields, A. P. Atypical Protein Kinase C ι Protects Human Leukemia Cells against Drug-Induced Apoptosis. J. Biol. Chem. 1997, 272, 27521-27524.
141. Jamieson, L.; Carpenter, L.; Biden, T. J.; Fields, A. P. Protein Kinase Cι Activity is Necessary for Bcr-Abl-Mediated Resistance to Drug-Induced Apoptosis. J. Biol. Chem. 1999, 274, 3927-3930.
142. Frutos, S.; Moscat, J.; Diaz-Meco, M. T. Cleavage of Zeta PKC but not Lamda/Iota PKC by Caspase-3 During UV-Induced Apoptosis. J. Biol. Chem. 1999, 274, 10765-10770.
143. Berra, E.; Municio, M, M.; Sanz, L.; Frutos, S.; Diaz-Meco, M. T.; Moscat, J. Positioning Atypical Protein Kinase C Isoforms in the UV Induced Apoptotic Signaling Cascade. Mol. Cell. Biol. 1997, 17, 4346-4354.
144. Muller, G.; Ayoub, M.; Storz, P.; Rennecke, J.; Fabbro, D.; Pfizenmaier, K. PKC Zeta is a Molecular Switch in Signal Transduction of TNF-Alpha, Bifunctionally Regulated by Ceramide and Arachidonic acid. EMBO J. 1995, 14, 1961-1969.
145. Hannun, Y. A. Functions of Ceramide in Coordinating Cellular Responses to Stress. Science 1998, 274, 1855-1859.
146. Obeid, L. M.; Linardic, C. M.; Karolak, L. A.; Hannun, Y. A. Programmed Cell Death Induced by Ceramide. Science 1993, 259, 1769-1771.
147. Lee, J. Y.; Hannun, Y. A.; Obeid, L. M. Ceramide Inactivates Cellular Protein Kinase C Alpha. J. Biol. Chem. 1996, 271, 13169-13174.
148. de Vente, J.; Kiley, S.; Garris, T.; Bryant, W.; Hooke, J.; Posekany, K. ; Parker, P. J.; Cook, P.; Fletcher, D.; Ways, D. K. Phorbol Ester Treatment of U937 Cells with Altered Protein Kinase C Content and Distribution Induces Cell Death Rather than Differentiation. Cell Growth Differ. 1995, 6, 371-382.
149. Dieter, P.; Fitzke, E. RO 31-8220 and RO 31-7549 Show Improved Selectivity for PKC Over Staurosporine in Macrophages. Biochem. Biophys. Res. Commun. 1991, 181, 396-401.
150. Yu, L.; Orlandi, L.; Wang, P.; Orr, M-S.; Senderowicz, A. M.; Sausville, E. A.; Silvestrini, R.; Watanabe, N.; Piwnica-Worms, H.; O'Connor, P. M. UCN-01 Abrogates G2 Arrest through a Cdc2-Dependent Pathway that is Associated with Inactivation of the WeelHu Kinase and Activation of the Cdc25C Phosphatase. J. Biol. Chem. 1998, 273, 33455-33464.
151. Shirahama, T.; Sakakura, C.; Sweeney, E. A.; Ozawa, M.; Takemoto, M.; Nishiyama, K.; Ohi, Y.; Igarashi, Y. Sphingosine Induces Apoptosis in Androgen-Independent Human Prostatic Carcinoma DU-145 Cells by Suppression of Bcl-X(L) Gene Expression. FEBS Lett. 1997, 407, 97-100.
152. Sakakura, C.; Sweeney, E. A.; Shirahama, T.; Hakomori, S.; Igarash, Y. Suppression of Bcl-2 Gene Expression by Sphingosine in the Apoptosis of Human Leukemic HL-60 Cells During Phorbol Ester-Induced Terminal Differentiation. FEBS Lett. 1996, 379, 177-180.
153. Han, Z.; Pantazis, P.; Lange, T. S.; Wyche, J. H.; Hendrickson, E. A. The Staurosporine Analog, Ro-31-8220, Induces Apoptosis Independently of its Ability to Inhibit Protein Kinase C. Cell Death Differ. 2000, 7, 521-530.
154. Ahmed, S.; Lee, J.; Kozma, R.; Best, A.; Monfries, C.; Lim, L. A. A Novel Functional Target for Tumor-Promoting Phorbol Esters and Lysophosphatidic Acid. The p21rac-GTPase Activating Protein N-Chimaerin. J. Biol. Chem. 1993, 268, 10709-10712.
155. Valverde, A. M.; Sinnett-Smith, J.; Van Lint, J.; Rozengurt, E. Molecular Cloning and Characterization of Protein Kinase D: a Target for Diacylglycerol and Phorbol Esters with a Distinctive Catalytic Domain. Proc. Natl. Acad. Sci. USA 1994, 91, 8572-8576.
156. Caloca, M. J.; Fernandez, N.; Lewin, N. E.; Ching, D.; Modali, R.; Blumberg, P. M.; Kazanietz, M. G. Beta2-Chimaerin is a High Affinity Receptor for the Phorbol Ester Tumor Promoters. J. Biol. Chem. 1997, 272, 26488-26496.
157. Shindo, M.; Irie, K.; Ohigashi, H.; Kuriyama, M.; Saito, N. Diacylglycerol Kinase Gamma is One of the Specific Receptors of Tumor-Promoting Phorbol Esters. Biochem. Biophys. Res. Commun. 2001, 289, 451-456.
158. Mayumi, S.; Azuma, A.; Kobayashi, H.; Sodeoka, M.; Yano, K.; Sugimoto, S.; Endo, Y.; Hashimoto, Y. Identification of Protein Disulfide Isomerase as a Phorbol Ester-Binding Protein. Biol. Pharm. Bull. 2000, 23, 1111-1113.
159. Watters, D. J.; Parsons, P. G. Critical Targets of Protein Kinase C in Differentiation of Tumour Cells. Biochem. Pharmacol. 1999, 58, 383-388.
160. Way, K. J.; Chou, E.; King, G. L. Identification of PKC-Isoform-Specific Biological Actions Using Pharmacological Approaches. Trends Pharmacol. Sci. 2000, 21, 181-187.
161. 1, γ, δ and ε by Phorbol Esters of Different Biological Activities. FEBS Lett. 1991, 288, 5-9.
162. 3. J. Biol. Chem. 1994, 269, 32358-32367.
163. Berkow, R. L.; Kraft, A. S. Bryostatin, a Nonphorbol Macrocyclic Lactone Activates Intact Human Polymorphonuclear Leukocytes and Binds to the Phorbol Ester Receptor. Biochem. Biophys. Res. Commun. 1989, 131, 1109-1115.
164. Blumberg, P. M. Complexities of the Protein Kinase C Pathway Mol. Carcinog. 1991, 4, 339-344.
165. Hocevar, B. A.; Fields, A. P. Selective Translocation of βII-PKC to the Nucleus of Human Promyelocytic (HL-60) Leukemia Cells. J. Biol. Chem. 1991, 266, 28-33.
166. Kennedy, M. J.; Prestigiacomo, L. J.; Tyler, G.; May, W, S.; Davidson, N. E. Differential Effects of Bryostatin 1 and Phorbol Ester on Human Breast Cancer Cell Lines. Cancer Res. 1992, 52, 1278-1283.
167. Gschwendt, M.; Fürstenberger, G.; Rose-John, S.; Rogers, M.; Kittstein, W.; Pettit, G. R.; Herald, C. L.; Marks, F. Bryostatin 1, an Activator of Protein Kinase C, Mimics as Well as Inhibits Biological Effects of the Phorbol Ester TPA in Vivo and in Vitro. Carcinogenesis 1988, 9, 555-562.
168. Dale, I. L.; Gescher, A. Effects of Activators of Protein Kinase C, Including Bryostatins 1 and 2, on the Growth of A549 Human Lung Carcinoma Cells. Int. J. Cancer 1989, 43, 158-163.
169. Lorenzo, P. S.; Beheshti, M.; Pettit, G. R.; Stone, J. C.; Blumberg, P. M. The Guanine Nucleotide Exchange Factor RasGRP is a High-Affinity Target for Diacylglycerol and Phorbol Esters. Mol. Pharmacol. 2000, 57, 840-846.
170. Rea, D.; Prendiville, J.; Harris, A. L.; Woll, P.; Philip, P.; Carmichael, J.; Lewis, C.; Dallma, M.; Walker, T.; Sri-Pathmanathan, E.; Thatcher, N.; Crowther, D. A Phase I Study of Bryostatin 1 - a PKC Partial Agonist. Ann. Oncol. 1992, 3, 62.
171. Jayson, G. C.; Crowther, D.; Prendiville, J.; McGown, A. T.; Scheid, C.; Stern, P.; Young, R.; Brenchley, P.; Chang, J.; Owens, S.; Pettit, G. R. A Phase I Trial of Bryostatin 1 in Patients with Advanced Malignancy Using a 24 Hour Intravenous Infusion. Br. J. Cancer 1995, 72, 461-468.
172. Grant, S.; Roberts, J.; Poplin, E.; Tombes, M. B.; Kyle B.; Welch, D.; Carr, M.; Bear, H. D. Phase Ib Trial of Bryostatin 1 in Patients with Refractory Malignancies. Clin. Cancer Res. 1998, 4, 611-618.
173. Varterasian, M. L.; Mohammad, R. M.; Eilender, D. S.; Hulburd, K.; Rodriguez, D. H.; Pemberton, P. A.; Pluda, J. M.; Dan, M. D.; Pettit, G. R.; Chen, B. D.; Al-Katib, A. M. Phase I Study of Bryostatin 1 in Patients with Relapsed Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. Clin. Oncol. 1998, 16, 56-62.
174. Varterasian, M. L.; Mohammad, R. M.; Shurafa, M. S.; Hulburd, K.; Pemberton, P. A.; Rodriguez, D. H.; Spadoni, V.; Eilender, D. S.; Murgo, A.; Wall, N.; Dan, M.; Al-Katib, A. M. Phase II Trial of Bryostatin 1 in Patients with Relapsed Low-Grade Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. Clin. Cancer Res. 2000, 6, 825-828.
175. Zonder, J. A.; Shields, A. F.; Zalupski, M.; Chaplen, R.; Heilbrun, L. K.; Arlauskas, P.; Philip, P. A. A Phase II Trial of Bryostatin 1 in the Treatment of Metastatic Colorectal Cancer. Clin. Cancer Res. 2001, 7, 38-42.
176. Brockstein, B.; Samuels, B.; Humerickhouse, R.; Arietta, R.; Fishkin, P. ; Wade, J.; Sosman, J.; Vokes, E. E. Phase II Studies of Bryostatin-1 in Patients with Advanced Sarcoma and Advanced Head and Neck Cancer. Invest. New Drugs 2001, 19, 249-254.
177. Pfister, D. G.; McCaffrey, J.; Zahalsky, A. J.; Schwartz, G. K.; Lis, E. ; Gerald, W.; Huvos, A.; Shah, J.; Kraus, D.; Shaha, A.; Singh, B.; Wolden, S.; Zelefsky, M.; Palgi, I. A Phase II Trial of Bryostatin-1 in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Invest. New Drugs 2002, 20, 123-127.
178. Propper, D. J.; Macaulay, V.; O'Byrne, K. J.; Braybrooke, J. P.; Wilner, S. M.; Ganesan, T. S.; Talbot, D. C.; Harris, A. L. A Phase II Study of Bryostatin 1 in Metastatic Malignant Melanoma. Br. J. Cancer 1998, 78, 1337-1341.
179. Tozer, R. G.; Burdette-Radoux, S.; Berlanger, K.; Davis, M. L.; Lohmann, R. C.; Rusthoven, J. R.; Wainman, N.; Zee, B.; Seymour, L. A Randomized Phase II Study of Two Schedules of Bryostatin-1 (NSC339555) in Patients with Advanced Malignant Melanoma: A National Cancer Institute of Canada Clinical Trials Group Study. Invest. New Drugs 2002, 20, 407-412.
180. Pagliaro, L.; Daliani, D.; Amato, R.; Tu, S. M.; Jones, D.; Smith, T. Logothetis, C.; Millikan, R. A Phase II Trial of Bryostatin-1 for Patients with Metastatic Renal Cell Carcinoma. Cancer 2000, 89, 615-618.
181. Hilgard, P.; Klenner, T.; Stekar, J.; Unger, C. Alkylphosphocholines: a New Class of Membrane-Active Anticancer Agents. Cancer Chemother. Pharmacol. 1993, 32, 90-95.
182. Brachwitz, H.; Vollgraf, C. Analogs of Alkyllysophospholipids: Chemistry, Effects on the Molecular Level and their Consequences for Normal and Malignant Cells. Pharmacol. Ther. 1995, 66, 39-82.
183. Clavel, M.; Mauriac, L.; Vennin, P.; Namer, M.; Maugard-Louboutin, C.; Goupil, A.; Veyret, C.; Sindermann, H.; David, M. Topically Applied Miltefosine (Hexadecylphosphocholine) in Cutaneous Relapses and/or Skin Metastasized Breast Cancer: a French Multicentric Study. Ann. Oncol. 1992, 3 (Suppl. 1), 65.
184. Klenner, T.; Engel, J.; Hilgard, P. Alkylphosphocholines: An Update. Drugs of Today 1998, 34, Suppl. F, Prous Science 1-2.
185. Kiss, Z.; Deli, E.; Vogler, W. R.; Kuo, J. F. Antileukemic Agent Alkyllysophospholipid Regulates Phosphorylation of Distinct Proteins in HL60 and K562 Cells and Differentiation of HL60 Cells Promoted by Phorbol Ester. Biochem. Biophys. Res. Commun. 1987, 142, 661-666.
186. Shoji, M.; Raynor, R. L.; Fleer, E. A.; Eibl, H.; Vogler, W. R.; Kuo, J. F. Effects of Hexadecylphosphocholine on Protein Kinase C and TPA-Induced Differentiation of HL60 Cells. Lipids 1991, 26, 145-149.
187. Civoli, F.; Daniel, L. W. Quaternary Ammonium Analogs of Ether Lipids Inhibit the Activation of Protein Kinase C and the Growth of Human Leukemia Cell Lines. Cancer Chemother. Pharmacol. 1998, 42, 319-326.
188. Berkovic, D.; Berkovic, K.; Flee, E. A.; Eibl, H.; Unger, C. Inhibition of Calcium-Dependent Protein Kinase C by Hexadecylphosphocholine and 1-O-Octadecyl-2-O-Methyl-rac-Glycero-3-Phosphocholine do not Correlate with Inhibition of Proliferation of HL60 and K562 Cell Lines. Eur. J. Cancer 1994, 30A, 509-515.
189. Heesbeen, E. C.; Verdonck, L. F.; Staal, G. E.; Rijksen, G. Protein Kinase C is not Involved in the Cytotoxic Action of 1-Octadecyl-2-O-Methyl-sn-Glycerol-3-Phosphocholine in HL-60 and K562 Cells. Biochem. Pharmacol. 1994, 47, 1481-1488.
190. Powis, G. Signalling Targets for Anticancer Drug Development. Trends Pharmacol. Sci. 1991, 12, 188-194.
191. Vogler, W. R.; Whigham, E.; Bennet, W. D.; Olson, A. C. Effect of Alkyllysophospholipids on Phosphatidylcholine Biosynthesis in Leukemic Cell Lines. Exp. Hematol. 1985, 13, 629-633.
192. Endo, K.; Igarashi, Y.; Nisar, M.; Zhou, Q. H.; Hakomori, S. Cell Membrane Signaling as Target in Cancer Therapy: Inhibitory Effect of N,N-Dimethyl and N,N,N-Trimethyl Sphingosine Derivatives on in Vitro and in Vivo Growth of Human Tumor Cells in Nude Mice. Cancer Res. 1991, 51, 1613-1618.
193. Sweatman, T. W.; Israel, M. Anthracyclines. In: Cancer Therapeutics: Experimental and Clinical Agents. Teicher.; B. A. Ed.; Humana Press Inc.; Totowa NJ, 1996, 113-136.
194. Roaten, J. B.; Kazanietz, M. G.; Sweatman, T. W.; Lothstein, L.; Israel, M.; Parrill, A. L. Molecular Models of N-Benzyladriamycin-14-Valerate (AD 198) in Complex with the Phorbol Ester-Binding Clb Domain of Protein Kinase C-Delta. J. Med. Chem. 2001, 44, 1028-1034.
195. Meyer, T.; Regenass, U.; Fabbro, D.; Alteri, E.; Rösel, J.; Müller, M.; Carvatti, G.; Matter, A. A Derivative of Staurosporine (CGP41251) Shows Selectivity for PKC Inhibition and in Vitro Antiproliferative as Well as in Vivo Antitumor Activity. Int. J. Cancer 1989, 43, 851-856.
196. Marte, B.; Meyer, T.; Stabel, S.; Standke, G. J.; Jaken, S.; Fabbro, D.; Hynes, N. E. Protein Kinase C and Mammary Cell Differentiation: Involvement of Protein Kinase C Alpha in the Induction of Beta-Casein Expression. Cell Growth Differ. 1994, 5, 239-247.
197. Dieter, P.; Fitzke, E. RO 31-8220 and RO 31-7549 Show Improved Selectivity for PKC over Staurosporine in Macrophages. Biochem. Biophys. Res. Commun. 1991, 181, 396-401.
198. Martiny-Baron, G.; Kazanietz, M. G.; Mischak, H.; Blumberg, P. M.; Kochs, G.; Hug, H.; Marme, D.; Schächtele, C. Selective Inhibition of Protein Kinase C Isozymes by the Indolocarbazole Go 6976. J. Biol. Chem. 1993, 268, 9194-9197.
199. Hu, H. Recent Discovery and Development of Selective Protein Kinase C Inhibitors. Drug Discov. Today 1996, 1, 438-447.
200. Toullec, D.; Pianetti, P.; Coste, H.; Bellevergue, P.; Grand-Perret, T.; Ajakane, M.; Baudet, V.; Boissing, P.; Boursier, E.; Loriolle, F.; Duhamel, L.; Charon, F.; Kirilovski, J. The Bis-Indolylmaleimide GF109203X is a Potent and Selective Inhibitor of PKC. J. Biol. Chem. 1991, 266, 15771-15781.
201. Seynaeve, C. M.; Kazanietz, M. G.; Blumberg, P. M.; Sausville, A. E.; Worland, P. J. Differential Inhibition of Protein Kinase C Isozymes by UCN-01, a Staurosporine Analogue. Mol. Pharmacol. 1994, 45, 1207-1214.
202. Zimmermann, J.; Caravatti, G.; Mett, H.; Meyer, T.; Muller, M.; Lydon, N. B.; Fabbro, D. Phenylamino-Pyrimidine (PAP) Derivatives: a New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC). Arch. Pharm. 1996, 329, 371-376.
203. Ishii, H.; Jirousek, M. R.; Koya, D.; Takagi, C.; Xia, P.; Clermont, A.; Bursell, S-E.; Kern, T. S.; Ballas, L. M.; Heath, W. F.; Stramm, L. E.; Feener, E. P.; King, G. L. Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKCβ Inhibitor. Science 1996, 272, 728-731.
204. Gschwendt, M.; Muller, H. J.; Kielbassa, K.; Zang, R.; Kittstein, W.; Rincke, G.; Marks, F. Rottlerin, a Novel Protein Kinase Inhibitor. Biochem. Biophys. Res. Commun. 1994, 199, 93-98.
205. Meggio, F.; Donella Deana, A.; Ruzzene, M.; Brunati, A. M.; Cesaro, L.; Guerra, B.; Meyer, T.; Mett, H.; Fabbro, D.; Furet, P.; Dobrowolska, A.; Pinna, L. A. Different Susceptibility of Protein Kinases to Staurosporine Inhibition. Kinetic Studies and Molecular Bases for Resistance of Protein Kinase CK2. Eur. J. Biochem. 1995, 234, 317-322.
206. Fabbro, D.; Buchdunger, E.; Wood, J.; Mestan, J.; Hofmann, F.; Ferrari, S.; Mett, H.; O'Reilly, T.; Meyer, T. Inhibitors of Protein Kinases: CGP41251, a Protein Kinase C Inhibitor with Potential as an Anticancer Agent. Pharmacol. Ther. 1999, 82, 293-301.
207. Courage, C.; Budworth, J.; Gescher, A. Comparison of Ability of Protein Kinase C Inhibitors to Arrest Cell Growth and to Alter Cellular Protein Kinase C Localisation. Br. J. Cancer 1995, 71, 697-704.
208. Fabbro, D.; Ruetz, S.; Bodis, S.; Pruschy, M.; Csermak, K.; Man, A.; Campochiaro, P.; Wood, J.; O'Reilly, T.; Meyer, T. PKC412 - a Protein Kinase Inhibitor with a Broad Therapeutic Potential. Anticancer Drug Des. 2000, 15, 17-28.
209. Weisberg, E.; Boulton, C.; Kelly, L. M.; Manley, P.; Fabbro, D.; Meyer, T.; Gilliland, D. G.; Griffin, J. D. Inhibition of Mutant FLT3 Receptors in Leukemia Cells by the Small Molecule Tyrosine Kinase inhibitor PKC412. Cancer Cell. 2002, 1, 433-443.
210. Pollak, I. F.; Kawecki, S.; Lazo, J. S. Blocking of Glioma Proliferation in Vitro and in Vivo and Potentiating the Effects of BCNU and Cis-Platin: UCN-01, a Selective Protein Kinase C Inhibitor. J. Neurosurg. 1996, 84, 1024-1032.
211. Akinaga, S.; Gomi, K.; Morimoto, M.; Tamaoki, T.; Okabe, M. Antitumor Activity of UCN-01, a Selective Inhibitor of Protein Kinase C, in Murine and Human Tumor Models. Cancer Res. 1991, 51, 4888-4892.
212. Sausville, E. A.; Lush, R. D.; Headlee, D.; Smith, A. C.; Figg, W. D.; Arbuck, S. G.; Senderowicz, A. M.; Fuse, E.; Tanii, H.; Kuwabara, T.; Kobayashi, S. Clinical Pharmacology of UCN-01: Initial Observations and Comparison to Preclinical Models. Cancer Chemother. Pharmacol. 1998, 42, Suppl, S54-S59.
213. Utz, I.; Spitaler, M.; Rybczynska, M.; Ludescher, C.; Hilbe, W.; Regenass, U.; Grunicke, H.; Hofmann, J. Reversal of Multidrug Resistance by the Staurosporine Derivatives CGP41251 and CGP 42700. Int. J. Cancer 1998, 77, 64-69.
214. Courage, C.; Bradder, S. M.; Jones, T.; Schultze-Mosgau, M. H.; Gescher, A. Characterisation of Novel Human Lung Carcinoma Cell Lines Selected for Resistance to Anti-Neoplastic Analogues of Staurosporine. Int. J. Cancer 1997, 73, 763-768.
215. Ikegami, Y.; Yano, S.; Nakao, K. Effects of the New Selective Kinase C Inhibitor 4′-N-Benzoyl Staurosporine on Cell Cycle Distribution and Growth Inhibition in Human Small Cell Lung Cancer Cells. Arzneim. Forsch. 1996, 46, 201-204.
216. Kakawami, K.; Futami, H.; Takahara, J.; Yamaguchi, K. UCN-01, 7-Hydroxyl-Staurosporine, Inhibits Kinase Activity of Cyclin-Dependent Kinases and Reduces Phosphorylation of the Retinoblastoma Susceptibility Gene Product in A549 Human Lung Cancer Cell Line. Biochem. Biophys. Res. Commun. 1996, 219, 778-783.
217. Teicher, B. A.; Menon, K.; Alvarez, E.; Liu, P.; Shih, C.; Faul, M. M. Antiangiogenic and Antitumor Effects of a Protein Kinase C Beta Inhibitor in Human Hepatocellular and Gastric Cancer Xenografts. In Vivo 2001, 15, 185-193.
218. Teicher, B. A.; Menon, K.; Alvarez, E.; Galbreath, E.; Shih, C.; Faul, M. Antiangiogenic and Antitumor Effects of a Protein Kinase C Beta Inhibitor in Human T98G Glioblastoma Multiforme Xenografts. Clin. Cancer Res. 2001, 7, 634-640.
219. Ahmad, S.; Mineta, T.; Martuza, R. L.; Glazer, R. I. Antisense Expression of Protein Kinase C Alpha Inhibits the Growth and Tumorigenictity of Human Glioblastoma Cells. Neurosurgery 1994, 35, 904-908.
220. Yazaki, T.; Ahmad, S.; Chahlavi, A.; Zylber-Katz, E.; Dean, N. M.; Rabkin, S. D.; Martuza, R. L.; Glazer, R. I. Treatment of Glioblastoma U-87 by Systemic Administration of an Antisense Protein Kinase C-Alpha Phosphorothiate Oligodeoxynucleotide. Mol. Pharmacol. 1996, 50, 236-242.
221. Dean, N.; McKay, R.; Miraglia, L.; Howard, R.; Cooper, S.; Giddings, J.; Nicklin, P.; Meister, L.; Ziel, R.; Geiger, T.; Muller, M.; Fabbro, D. Inhibition of Growth of Human Tumor Cell Lines in Nude Mice by an Antisense Oligonucleotide Inhibitor of Protein Kinase C-α Expression. Cancer Res. 1996, 56, 3499-3507.
222. Geiger, T.; Muller, M.; Dean, N. M.; Fabbro, D. Antitumor Activity of a PKC-Alpha Antisense Oligonucleotide in Combination with Standard Chemotherapeutic Agents against Various Human Tumors Transplanted into Nude Mice. Anticancer Drug Des. 1998, 13, 35-45.
223. Benimetskaya, L.; Miller, P.; Benimetsky, S.; Maciaszek, A.; Guga, P.; Beaucage, S. L.; Wilk, A.; Grajkowski, A.; Halperin, A. L.; Stein, C. A. Inhibition of Potentially Anti-Apoptotic Proteins by Antisense Protein Kinase C-Alpha (ISIS 3521) and Antisense Bcl-2 (G3139) Phosphorothioate Oligodeoxynucleotides: Relationship to the Decreased Viability of T24 Bladder and PC3 Prostate Cancer Cells. Mol. Pharmacol. 2001, 60, 1296-307.
224. Dennis, J. U.; Dean, N. M.; Bennett, C. F.; Griffith, J. W.; Lang, C. M. ; Welch, D. R. Human Melanoma Metastasis is Inhibited Following ex Vivo Treatment with an Antisense Oligonucleotide to Protein Kinase C-Alpha. Cancer Lett. 1998, 128, 65-70.
225. Wang, X. Y.; Repasky, E.; Liu, H. T. Antisense Inhibition of Protein Kinase C Alpha Reverses the Transformed Phenotype in Human Lung Carcinoma Cells. Exp. Cell Res. 1999, 250, 253-263.
226. Denham, D. W.; Franz, M. G.; Denham, W.; Zervo, E. E.; Gower, W. R. Jr.; Rosemurgy, A. S.; Norman, J. Directed Antisense Therapy Confirms the Role of Protein Kinase C-Alpha in the Tumorigenicity of Pancreatic Cancer. Surgery 1998, 124, 218-224.
227. Nemunaitis, J.; Holmlund, J. T.; Kraynak, M.; Richards, D.; Bruce, J.; Ognoskie, N.; Kwoh, T. J.; Geary, R.; Dorr, A.; Von Hoff, D.; Eckhardt, S. G. Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients with Advanced Cancer. J. Clin. Oncol. 1999, 17, 3586-3595.
228. Yuen, A. R.; Halsey, J.; Lum, B.; Fisher, G.; Advani, R.;, Geary, R.; Kwoh, T. J.; Holmlund, J. T.; Dorr, A:; Sikic, B. I. Phase I/II Trial of ISIS-3521, an Antisense Inhibitor of Protein Kinase C-Alpha, with Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer. NCI/EORTC Syposium on New Drugs for Cancer Therapy, Amsterdam, 2000, 529.
229. Cripps, M. C.; Figueredo, A. T.; Oza, A. M.; Taylor, M. J.; Fields, A. L.; Holmlund, J. T.; McIntosh, L. W.; Geary, R. S.; Eisenhauer, E. A. Phase II Randomized Study of ISIS 3521 and ISIS 5132 in Patients with Locally Advanced or Metastatic Colorectal Cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Clin. Cancer Res. 2002, 8, 2188-2192.
230. Spitaler, M.; Wiesenhofer, B.; Biedermann, V.; Seppi, T.; Zimmermann, J. ; Grunicke, H.; Hofmann, J. The Involvement of Protein Kinase C Isozymes α, ε and ζ in the Sensitivity to Antitumor Treatment and Apoptosis Induction. Anticancer Res. 1999, 19, 3969-3976.
231. Hofmann, J. Modulation of Protein Kinase C in Antitumor Treatment. Rev. Physiol. Biochem. Pharmacol. 2001, 142, 1-96.
232. Ferry, D. R.; Smith, A.; Malkhandi, J.; Fyfe, D. W.; deTakats, P. G.; Anderson, D.; Baker, J.; Kerr, D. J. Phase I Clinical Trial of the Flavonoid Quercetin: Pharmacokinetics and Evidence for in Vivo Tyrosine Kinase Inhibition. Clin. Cancer Res. 1996, 2, 659-668.
233. Fyfe, D.; Ferry, D. R.; Smith, A.; de Takats, P.; Baker, J. Kerr, D. J. Phase I Clinical Trial of the Tyrosine Kinase Inhibitor Quercetin Combined with Carboplatin in Advanced Cancer. Ann. Oncology 1996, 7, Suppl. 1, 263.
234. Larocca, L. M.; Teofili, L.; Sica, S.; Piantelli, M.; Maggiano, N.; Leone, G.; Ranelletti, F. O. Quercetin Inhibits the Growth of Leukemic Progenitors and Induces the Expression of Transforming Growth Factor-Beta I in these Cells. Blood 1995, 85, 3654-3661.
235. Isonishi, S.; Andrews, P. A.; Howell, S. B. Increased Sensitivity to Cis Diamminedichloroplatinum(II) in Human Ovarian Carcinoma Cells in Response to Treatment with 12-O-Tetradecanoylphorbol-13-Acetate. J. Biol. Chem. 1990, 265, 3623-3627.
236. Basu, A.; Teicher, B. A.; Lazo, J. S. Involvement of Protein Kinase C in Phorbol Ester-Induced Sensitization of HeLa Cells to Cis-Diamminedichloroplatinum(II). J. Biol. Chem. 1990, 265, 8451-8457.
237. O'Brian, C. A.; Ward, N. E.; Gravitt, K. R.; Gupta, K. P. The Tumor Promoter Receptor Protein Kinase C: a Novel Target for Chemoprevention and Therapy of Human Colon Cancer. Prog. Clin. Biol. Res. 1995, 391, 117-120.
238. Blackburn, R. V.; Galoforo, S. S.; Berns, C. M.; Motwani, N. M.; Corry, P. M.; Lee, Y. J. Differential Induction of Cell Death in Human Glioma Cell Lines by Sodium Nitroprusside. Cancer 1998, 82, 1137-1145.
239. Chakrabarty, S.; Huang, S. Modulation of Chemosensitivity in Human Colon Carcinoma Cells by Down-Regulating Protein Kinase C Alpha Expression. J. Exp. Ther. Oncol. 1996, 1, 218-221.
240. Basu, A.; Weixel, K. M. Comparison of Protein Kinase C Activity and Isoform Expression in Cisplatin-Sensitive and -Resistant Ovarian Carcinoma Cells. Int. J. Cancer 1995, 62, 457-460.
241. Ohmori, T.; Arteaga, C. L. Protein Kinase C Epsilon Translocation and Phosphorylation by Cis-Diamminedichloroplatinum(II) (CDDP): Potential Role in CDDP-Mediated Cytotoxicity. Cell Growth Differ. 1998, 9, 345-353.
242. Basu, A.; Weixel, K.; Saijo, N. Characterization of the Protein Kinase C Signal Transduction Pathway in Cisplatin-Sensitive and -Resistant Human Small Cell Lung Carcinoma Cells. Cell Growth Differ. 1996, 7, 1507-1512.
243. La Porta, C. A. M.; Dolfini, E.; Comolli, R. Inhibition of Protein Kinase C-α Isoform Enhances the P-Glycoprotein Expression and the Survival of LoVo Human Colon Adenocarcinoma Cells to Doxorubicin Exposure. Br. J. Cancer 1998, 78, 1283-1287.
244. Gottesman, M. M. Pastan, I. Biochemistry of Multidrug Resistance Mediated by the Multidrug Transporter. Annu. Rev. Biochem. 1993, 62, 385-427.
245. Cloud-Heflin, B. A.; McMasters, R. A.; Osborn, M. T.; Chambers, T. C. Expression, Subcellular Distribution and Response to Phorbol Esters of Protein Kinase C (PKC) Isozymes in Drug-Sensitive and Multidrug-Resistant KB Cells. Evidence for Altered Regulation of PKC-Alpha. Eur. J. Biochem. 1996, 239, 796-804.
246. Blobe, G. C.; Sachs, C. W.; Khan, W. A.; Fabbro, D.; Stabel, S.; Wetsel, W. C.; Obeid, L. M.; Fine, R. L.; Hannun, Y. A. Selective Regulation of Expression of Protein Kinase C (PKC) Isozymes in Multidrug-Resistant MCF-7 Cells. Functional Significance of Enhanced Expression of PKCα. J. Biol. Chem. 1993, 268, 658-664.
247. Budworth, J.; Gant, T. W.; Gescher, A. Co-Ordinate Loss of Protein Kinase C and Multidrug Resistance Gene Expression in Revertant MCF-7/Adr Breast Carcinoma Cells. Br. J. Cancer 1997, 75, 1330-1335.
248. Gill, P. K.; Gescher, A.; Gant, T. W. Regulation of MDR1 Promoter Activity in Human Breast Carcinoma Cells by Protein Kinase C Isozymes Alpha and Theta. Eur. J. Biochem. 2001, 268, 4151-4157.
249. Dolfini, E.; Dasdia, T.; Perletti, G.; Romagnoni, M.; Piccinini, F. Analysis of Calcium-Dependent Protein Kinase-C Isozymes in Intrinsically Resistant Cloned Lines of LoVo Cells: Reversal of Resistance by KINASE Inhibitor 1-(5-Isoquinolinylsulfonyl) 2-Methylpiperazine. Anticancer Res. 1993, 13, 1123-1127
250. Yu, G.; Ahmad, S.; Aquino, A.; Fairchild, C. R.; Trepel, J. B.; Ohno, S. ; Suzuki, K.; Tsuruo, T.; Cowan, K. H.; Glazer, R. I. Transfection with Protein Kinase Cα Confers Increased Multidrug Resistance to MCF-7 Cells Expressing P-Glycoprotein. Cancer Commun. 1991, 3, 181-189.
251. Ahmad, S.; Glazer, R. I. Expression of the Antisense cDNA for Protein Kinase C Alpha Attenuates Resistance in Doxorubicin-Resistant MCF-7 Breast Carcinoma Cells. Mol. Pharmacol. 1993, 43, 858-862.
252. Gravitt, K. R.; Ward, N. E.; Fan, D.; Skibber, J. M.; Levin, B.; O'Brian, C. A. Evidence that Protein Kinase C-Alpha Activation is a Critical Event in Phorbol Ester-Induced Multiple Drug Resistance in Human Colon Cancer Cells. Biochem. Pharmacol. 1994, 48, 375-381.
253. Matsumoto, T.; Tani, E.; Yamaura, I.; Miyaji, K.; Kaba, K. Effects of Protein Kinase C Modulators on Multidrug Resistance in Human Glioma Cells. Neurosurgery 1995, 36, 565-571.
254. Gekeler, V.; Boer, R.; Überall, F.; Ise, W.; Schubert, C.; Utz, I.; Hofmann, J.; Sanders, K. H.; Schächtele, C.; Klemm, K.; Grunicke, H. Effects of the Selective Bisindolylmaleimide Protein Kinase C Inhibitor GF 109203X on P-Glycoprotein-Mediated Multidrug Resistance. Br. J. Cancer 1996, 74, 897-905.
255. Gupta, K. P.; Ward, N. E.; Gravitt, K. R.; Bergman, P. J.; O'Brian, C. A. Partial Reversal of Multidrug Resistance in Human Breast Cancer Cells by an N-Myristoylated Protein Kinase C-Alpha Pseudosubstrate Peptide. J. Biol. Chem. 1996, 271, 2102-2111.
256. Bergman, P. J.; Gravitt, K. R.; Ward, N. E.; Beltran, P.; Gupta, K. P.; O'Brian, C. A. Potent Inuduction of Human Colon Cancer Cell Uptake of Chemotherapeutic Drugs by N-Myristoylated Protein Kinase C-Alpha (PKC-Alpha) Pseudosubstrate Peptides through a P-Glycoprotein-Independent Mechanism. Invest. New Drugs 1997, 15, 311-318.
257. Masanek, U.; Stammler, G.; Volm, M. Messenger RNA Expression of Resistance Proteins and Related Factors in Human Ovarian Carcinoma Cell Lines Resistant to Doxorubicin, Taxol and Cisplatin. Anticancer Drugs 1997, 8, 189-198.
258. Beck, J.; Handgretinger, R.; Klingebiel, T.; Dopfer, R.; Schaich, M.; Ehninger, G.; Niethammer, D.; Gekeler, V. Expression of PKC Isozyme and MDR-Associated Genes in Primary and Relapsed State AML. Leukemia 1996, 10, 426-433.
259. Beck, J.; Bohnet, B.; Brugger, D.; Bader, P.; Dietl, J.; Scheper, R. J.; Kandolf, R.; Liu, C.; Niethammer, D.; Gekeler, V. Multiple Gene Expression Analysis Reveals Distinct Differences between G2 and G3 Stage Breast Cancers, and Correlations of PKC Eta with MDR1, MRP and LRP Gene Expression. Br. J. Cancer 1998, 77, 87-91.
260. Hu, Y. P.; Robert, J. Inhibition of protein kinase C in multidrug-resistant cells by modulators of multidrug resistance. J. Cancer Res. Clin. Oncol. 1997, 123, 201-210.
261. Zheng, B.; Chambers, T. C.; Raynor, R. L.; Markham, P. N.; Gebel, H. M.; Vogler, W. R.; Kuo, J. F. Human Leukemia K562 Cell Mutant (K562/OA200) Selected for Resistance to Okadaic Acid (Protein Phosphatase Inhibitor) Lacks Protein Kinase C Epsilon, Exhibits Multidrug Resistance Phenotype, and Expresses Drug Pump P-Glycoprotein. J. Biol. Chem. 1994, 269, 12332-12338.
262. Conseil, G.; Perez-Victoria, J. M.; Jault, J. M.; Gamarro, F.; Goffeau, A.; Hofmann, J.; Di Pietro, A. Protein Kinase C Effectors Bind to Multidrug ABC Transporters and Inhibit their Activity. Biochemistry 2001, 40, 2564-2571.
263. Galski, H.; Lazarovici, P.; Gottesman, M. M.; Murakata, C.; Matsuda, Y.; Hochman, J. KT-5720 Reverses Multidrug Resistance in Variant S49 Mouse Lymphoma Cells Transduced with the Human MDR1 cDNA and in Human Multidrug-Resistant Carcinoma Cells. Eur. J. Cancer 1995, 31A, 380-388.
264. Budworth, J.; Davis, R.; Malkhandi, J.; Gant, T. W.; Ferry, D. R.; Gescher, A. Comparison of Staurosporine and Four Analogues: Their Effects on Growth, Rhodamine 123 Retention and Binding to P-Glycoprotein in Multidrug-Resistant MCF-7/Adr Cells. Br. J. Cancer 1996, 73, 1063-1068.
265. Merrit, J. E.; Sullivan, J. A.; Drew, L.; Khan, A.; Wilson, K.; Mulqueen, M.; Harris, W.; Bradshaw, D.; Hill, C. H.; Rumsby, M.; Warr, R. The Bisindolylmaleimide Protein Kinase C Inhibitor, Ro 32-2241, Reverses Multidrug Resistance in KB Tumour Cells. Cancer Chemother. Pharmacol. 1999, 43, 371-378.
266. Hofmann, J.; Gekeler, V.; Ise, W.; Noller, A.; Mitterdorfer, J.; Hofer, S.; Utz, I.; Gotwald, M.; Boer, R.; Glossmann, H.; Grunicke, H. Mechanism of Action of Dexniguldipine-HCl (B8509-035), a New Potent Modulator of Multidrug Resistance. Biochem. Pharmacol. 1995, 49, 603-609.
267. Hofmann, J.; Utz, I.; Spitaler, M.; Hofer, S.; Rybczynska, M.; Beck W. T.; Herrmann, D. B. J.; Grunicke, H. Resistance to the New Anti-Cancer Phospholipid Ilmofosine (BM 41 440). Br. J. Cancer 1997, 76, 862-869.
268. Rybczynska, M.; Liu, R.; Lu, P.; Sharom, F. J.; Steinfels, E.; Pietro, A. D.; Spitaler, M.; Grunicke, H.; Hofmann, J. MDR1 Causes Resistance to the Antitumour Drug Miltefosine. Br. J. Cancer 2001, 84, 1405-1411.
269. Chambers, T. C.; Pohl, J.; Raynor, R. L.; Kuo, J. F. Identification of Specific Sites in Human P-Glycoprotein Phosphorylated by Protein Kinase C. J. Biol. Chem. 1993, 268, 4592-4595.
270. Yang, J. M.; Chin, K. V.; Hait, W. N. Interaction of P-Glycoprotein with Protein Kinase C in Human Multidrug Resistant Carcinoma Cells. Cancer Res. 1996, 56, 3490-3494.
271. Ahmad, S.; Trepel, J. B.; Ohno, S.; Suzuki, K.; Tsuruo, T.; Glazer, R. I. Role of Protein Kinase C in the Modulation of Multidrug Resistance: Expression of the Atypical Gamma Isoform of Protein Kinase C does not Confer Increased Resistance to Doxorubicin. Mol. Pharmacol. 1992, 42, 1004-1009.
272. Chambers, T. C.; Pohl, J.; Glass, D. B.; Kuo, J. F. Phosphorylation by Protein Kinase C and Cyclic AMP-Dependent Protein Kinase of Synthetic Peptides Derived from the Linker Region of Human P-Glycoprotein. Biochem. J. 1994, 299, 309-315.
273. Scala, S.; Dickstein, B.; Regis, J.; Szallasi, Z.; Blumberg, P. M.; Bates, S. E. Bryostatin 1 Affects P-Glycoprotein Phosphorylation but not Function in Multidrug-Resistant Human Breast Cancer Cells. Clinical Cancer Res. 1995, 1, 15851-1587.
274. Goodfellow, H. R.; Sardini, A.; Ruetz, S.; Callaghan, R.; Gros, P.; McNaughton, P. A, and Higgins CF Protein Kinase C-Mediated Phosphorylation does not Regulate Drug Transport by the Human Multidrug Resistance P-Glycoprotein. J. Biol. Chem. 1996, 271, 13668-13674.
275. Germann, U. A.; Chambers, T. C.; Ambudkar, S. V.; Licht, T.; Cardarelli, C. O.; Pastan, I.; Gottesman, M. M. Characterization of Phosphorylation-Defective Mutants of Human P-Glycoprotein Expressed in Mammalian Cells. J. Biol. Chem. 1996, 217, 1708-1716.
276. Staats, J.; Marquardt, D.; Center, M. S. Characterization of a Membrane-Associated Protein Kinase of Multidrug-Resistant HL60 Cells which Phosphorylates P-Glycoprotein. J. Biol. Chem. 1990, 265, 4084-4090.
277. Hardy, S. P.; Goodfellow, H. R.; Valverde, M. A.; Gill, D. R.; Sepulveda, V.; Higgins, C. F. Protein Kinase C-Mediated Phosphorylation of the Human Multidrug Resistance P-Glycoprotein Regulates Cell Volume-Activated Chloride Channels. EMBO J. 1995, 14, 68-75.
278. Utz, I.; Hofer, S.; Regenass, U.; Hilbe, W.; Thaler, J.; Grunicke, H.; Hofmann, J. The Protein Kinase C Inhibitor CGP41251, a Staurosporine Derivative with Antitumor Activity, Reverses Multidrug Resistance. Int. J. Cancer 1994, 57, 104-110.
279. Beltran, P. J.; Fan, D.; Fidler, I. J.; O'Brian, C. A. Chemosensitization of Cancer Cells by the Staurosporine Derivative CGP41251 in Association with Decreased P-Glycoprotein Phosphorylation. Biochem. Pharmacol. 1997, 53, 245-247.
280. Chaudhary, P. M.; Roninson, I. B. Induction of Multidrug Resistance in Human Cells by Transient Exposure to Different Chemotherapeutic Drugs. J. Natl. Cancer Inst. 1993, 85, 532-539.
281. Flescher, E.; Rotem, R. Protein Kinase C Epsilon Mediates the Induction of P-Glycoprotein in LNCaP Prostate Carcinoma Cells. Cell. Signal. 2002, 14, 37-43.
282. Dolfini, E.; Dasdiac, T.; Arancia, G.; Molinari, A.; Calcabrini, A.; Scheper, R. J.; Flens, M. J.; Gariboldi, M. B.; Monti, E. Characterization of a Clonal Human Colon Adenocarcinoma Line Intrinsically Resistant to Doxorubicin. Br. J. Cancer 1997, 76, 67-76.
283. Huang, M.; Wang, Y.; Cogut, S. B.; Mitchell, B. S.; Graves, L. M. Inhibition of Nucleoside Transport by Protein Kinase Inhibitors. J. Pharmacol. Exp. Ther. 2003, 304, 753-760.
284. Kiley, S. C.; Clark, K. J.; Duddy, S. K.; Welch, D. R.; Jaken, S. Increased Protein Kinase C Delta in Mammary Tumor Cells: Relationship to Transformtion and Metastatic Progression. Oncogene 1999, 18, 6748-6757.
285. Smith, T. A. Hydroxyurea Treatment Enhances Metastatic Cell Adhesiveness: a Possible Chemotherapy-Induced Increase in Metastatic Potential? Anticancer Drugs 1999, 10, 429-430.
286. Diaz-Meco, M. T.; Municio, M. M.; Frutos, S.; Sanchez, P.; Lozano, J.; Sanz, L.; Moscat, J. The Product of Par-4, a Gene Induced During Apoptosis, Interacts Selectively with the Atypical Isoforms of Protein Kinase C. Cell 1996, 86, 777-786.